Cel Sci Corporation (CVM)

[GD]

One thing I really do not like is Geert's comments of comparing how many
death one group to another group is so idiotic, I have to remind Geert
that, to FDA, the primary OS endpoint is pre-specified in statistical plan
and the p value has to be statistical significant for approval, the sub-
group data how many patients can be cured is not in SAP for approval but
only meaningful for marketing purpose, IMO.
Please listen the interview again, pay attention at time market 35 to 36
minute, Geert should know better, what do you think?